EAM
APGE icon

Exome Asset Management’s Apogee Therapeutics APGE Stock Holding History

Exome Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-94,400
Closed -$3.75M – 63
2025
Q3 		$3.75M Buy
+94,400
New +$3.6M 2.27% 13

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Exome Asset Management's APGE Position: Q4 2025 in Review

Exome Asset Management sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 94,400 shares — an estimated $3.75M sold.

Exome Asset Management first reported a position in APGE in Q3 2025 and held it in 1 quarter. The position peaked at $3.75M in Q3 2025. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • Exome Asset Management reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Exome Asset Management sold 94,400 Apogee Therapeutics shares in Q4 2025, an estimated $3.75M.
  • Exome Asset Management first reported a position in Apogee Therapeutics in Q3 2025 and held it in 1 quarter.
  • Exome Asset Management's Apogee Therapeutics position peaked at $3.75M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.